{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Marqibo%C2%AE+%28vincristine+sulfate+liposomes+injection%29", "query": { "intervention": "Marqibo® (vincristine sulfate liposomes injection)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T17:35:04.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02257242", "title": "Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Lymphoma, Small-Cell", "Waldenstrom Macroglobulinemia", "Lymphoma, B-Cell, Marginal Zone" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Vincristine sulfate liposome injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-05-10", "completion_date": "2020-11-18", "has_results": true, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257242" }, { "nct_id": "NCT01859819", "title": "Treatment for Advanced B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large Cell Lymphoma", "Burkitt's Lymphoma", "High Grade B-cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "IT Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "3 Years to 31 Years" }, "enrollment_count": 45, "start_date": "2013-01", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 5, "location_summary": "Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859819" }, { "nct_id": "NCT01222780", "title": "To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Neuroblastoma", "Wilms Tumor", "Leukemia", "Lymphoma", "Brain Tumors" ], "interventions": [ { "name": "Marqibo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 22, "start_date": "2010-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222780" }, { "nct_id": "NCT00506142", "title": "Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Uveal Melanoma" ], "interventions": [ { "name": "Marqibo® (vincristine sulfate liposomes injection)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2007-11", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-12-11", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 4, "location_summary": "Los Angeles, California • Denver, Colorado • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00506142" }, { "nct_id": "NCT02518750", "title": "Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoma, Non-Hodgkin's", "Leukemia, T-Cell", "Leukemia, B-Cell" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Liposomal vincristine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Peg-asparaginase", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Intrathecal Triples", "type": "DRUG" }, { "name": "High-dose methotrexate", "type": "DRUG" }, { "name": "6-Mercaptopurine", "type": "DRUG" }, { "name": "High-dose cytarabine", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3, "start_date": "2016-11-23", "completion_date": "2018-03-11", "has_results": true, "last_update_posted_date": "2019-04-03", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02518750" }, { "nct_id": "NCT02879643", "title": "Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALL, Childhood", "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Leukemia, Acute" ], "interventions": [ { "name": "Marqibo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 29, "start_date": "2017-01-31", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 28, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879643" }, { "nct_id": "NCT00201695", "title": "Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Doxil®", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Arsenic Trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-07", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2015-06-10", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201695" }, { "nct_id": "NCT01439347", "title": "A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)" ], "interventions": [ { "name": "Vincristine Sulfate Liposomes Injection (VSLI)", "type": "DRUG" }, { "name": "Vincristine Sulfate Injection (VSI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 26, "start_date": "2012-03", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 15, "location_summary": "La Jolla, California • Los Angeles, California • Atlanta, Georgia + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01439347" }, { "nct_id": "NCT04448834", "title": "Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dorothy Sipkins, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-01", "completion_date": "2023-06-01", "has_results": false, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 3, "location_summary": "Tampa, Florida • Durham, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04448834" }, { "nct_id": "NCT00495079", "title": "Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)" ], "interventions": [ { "name": "Marqibo® (vincristine sulfate liposomes injection)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2007-05", "completion_date": "2010-08-08", "has_results": true, "last_update_posted_date": "2021-03-05", "last_synced_at": "2026-10-09T17:35:04.956Z", "location_count": 18, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00495079" } ] }